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Abstract We report the synthesis of three stereoisomers of a mycolic
acid from Mycobacterium tuberculosis containing a di-cis-cyclopropane
and of two stereoisomers of a mycolic acid containing a proximal trans-
cyclopropane and a distal cis-cyclopropane.
Key words mycolic acid, cis-cyclopropane, trans-cyclopropane,
stereoisomers
Mycolic acids (MA) from mycobacteria, having a general
structure 1 (Figure 1), usually containing 70 to 90 carbons,
are present as complex mixtures with varying chain lengths
and a number of combinations of distal and proximal sub-
stituents X and Y, and different exact compositions depend-
ing on the species.1–7
Figure 1  General structure of mycolic acids
Commonly, group Y is a cis- or α-methyl substituted
trans-cyclopropane, a cis-alkene or a trans-alkene with an
adjacent methyl substituent. Group X is a cis-cyclopropane
(α- and α′-MA), a -CHMeCHOMe- fragment (methoxy-MA)
or a -CHMeCO- fragment (keto-MA). Structural assignment
has often been based on mass spectra of mixtures of homo-
logues or fragments from them.8,9 It is often difficult from
the early literature to judge the certainty with which a
structure has been assigned or, indeed, which actual values
of a–d have been determined. However, recent detailed
studies have clarified the situation considerably.8,9 The
presence and proportion of individual classes of MA, and in
particular cyclopropanated MA, is known to be important
for the virulence of diseases such as tuberculosis.10–13 The
free MA are themselves strongly bioactive and indeed syn-
thetic MA of different classes, matching the structures of
components of natural mixtures, are selectively active.14
Among the most abundant of these acids are α-MAs
containing two cis-cyclopropanes (2).8,9 The acid 2 (a = 19, b
= 14, c = 11, d = 23) was reported by Minnikin and Polgar to
be the major MA of Mycobacterium tuberculosis var homi-
nis.15 (Figure 2)
Figure 2  Typical α-mycolic acid chain lengths
Indeed, such α-MA make up around 50% of the MA iso-
lated from Mtb cells.7 Although the hydroxy-acid grouping
is known to be of R,R-configuration, the absolute stereo-
chemistries of the cyclopropanes are not always clearly de-
fined. There is evidence that the 1-methyl-2-methoxy unit
at the distal position from the hydroxy acid in methoxy-MA
is S,S,16,17 while the corresponding carbon bearing a methyl
group in ketomycolates is also S.18 Much is now known
about the enzymes controlling the biosynthesis of MA,19–23
and it has been proposed, for example, that the cis-cyclo-
propane unit, the α-methyl-trans-cyclopropane and the α-
methyl-β-alkoxy unit are formed from a Z-alkene through a
common intermediate (Scheme 1).24,25 A consequence of
OH
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C. Don Lawson et al. PaperSyn Openthis would be that the three subunits should have a com-
mon absolute stereochemistry at the carbon bearing the
methyl group and C-1 of the cis-cyclopropane.
Scheme 1  Proposed common formal intermediate cation in MA bio-
synthesis
The stereochemistry B of the trans-cyclopropane unit is
consistent with NMR spectra and optical rotations of this
fragment in methoxy-MA,26 and with that of the distal posi-
tion in methoxy- and keto-MA, and on this basis the cis-
cyclopropane stereochemistry is likely to be A. However,
there is little direct evidence that this is the case, and an al-
ternative possibility is that the cis-isomer is produced with
an alternative stereochemistry in the enzyme-promoted
cyclopropanation, or indeed that a mixture of stereoiso-
mers is produced. Although the isomer with stereochemis-
try A at both cyclopropanes, compound 2a (Figure 3) was
reported some time ago,27,28 and has been shown to have
significant biological activity in a number of contexts,14,29
we now describe the synthesis of the three other stereoiso-
mers of 2 containing two cis-cyclopropanes in order that
their biological properties may be compared to those of 2a.
Figure 3  First synthetic α-mycolic acid
The synthetic method used, a simple extension of the
method used to prepare 2a, involved the use of a common
precursor for the two chiral cyclopropane units, with C–C
bonds being created at the positions shown in Figure 4.
The (1S,2R)-aldehyde 3 was prepared by a method de-
scribed earlier from (1S,2R)-butyryloxymethyl-2-formylcy-
clopropane.28,30,31 Reaction of (1R)-butyryloxymethyl-(2S)-
formyl-cyclopropane 5 with sulfone 4 in a similar way
(Scheme 2) led to the (1R,2S)-aldehyde 6.
Scheme 2  Reagents and conditions: (i) 4, LiHMDS, THF (80%); (ii) LiAlH4, 
THF (90%); (iii) N2H4, NaIO4, AcOH, CuSO4, iPrOH (83%); (iv) PCC, CH2Cl2 
(90%).
The aldehyde 6 was homologated to give 8 by reaction
with sulfone 7 and base, again to give a mixture of E-and Z-
alkenes, followed by reduction to the corresponding alco-
hols, hydrogenation of the alkenes using di-imide, and then
oxidation to the aldehyde 9, or converted into the sulfone
10 (Scheme 3).
Scheme 3  Reagents and conditions: (i) LiHMDS, THF (98%); (ii) LiAlH4, 
THF (91%); (iii) N2H4, NaIO4, AcOH, CuSO4, iPrOH (75%); (iv) PCC, CH2Cl2 
(84%) (v) 1-phenyl-1H-tetrazole-5-thiol, PPh3, DEAD (97%); (vi) 3-chloro-
peroxybenzoic acid, NaHCO3 CH2Cl2 (67%).
The proximal cyclopropane unit 1132,33 was treated with
aldehyde 9 in a modified Julia reaction,21 to give a 1:1 mix-
ture of E- and Z-alkenes. Reduction of the esters to the cor-
responding alcohols using lithium aluminium hydride, fol-
lowed by hydrogenation of the alkene, again using di-imide,
gave a single enantiomer of alcohol 12 (Scheme 4).
Scheme 4  Reagents and conditions: (i) LiHMDS, THF (65%); (ii) LiAlH4, 
THF (89%); (iii) N2H4, NaIO4, AcOH, CuSO4, iPrOH (63%).
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C. Don Lawson et al. PaperSyn OpenSulfone 10 was coupled to aldehyde 13 prepared as be-
fore,33,34 followed again by reduction of the derived E/Z-
mixture of esters to the corresponding alcohols and then
saturation of the alkenes (Scheme 5).
Scheme 5  Reagents and conditions: (i) LiHMDS, THF (62%); (ii) LiAlH4, 
THF (72%); (iii) N2H4, NaIO4, AcOH, CuSO4, iPrOH (71%).
The fourth stereoisomer (16) was prepared by a similar
method using 15 (prepared in a similar way to 10; see the
Supporting Information) and the aldehyde 5 (Scheme 6).
Scheme 6  Reagents and conditions: (i) LiHMDS, THF (78%); (ii) LiAlH4, 
THF (50%); (iii) N2H4, NaIO4, AcOH, CuSO4, iPrOH (63%).
Each of the alcohols 12, 14 and 16 was then converted
into the corresponding sulfone 17, 18 and 19 (Scheme 7).
Scheme 7  Reagents and conditions: (i) 1-phenyl-1H-tetrazole-5-thiol, 
PPh3, diethyl azodicarboxylate (93%); (ii) 3-chloroperoxybenzoic acid, 
NaHCO3 CH2Cl2 (85%).
Coupling of these with the protected hydroxy-acid frag-
ment 20, followed by hydrogenation of the derived alkenes
and then deprotection, led to the three stereoisomers, 22,
23 and 24 (Scheme 8).
Scheme 8  Reagents and conditions: (i) LiHMDS, THF (87%); 
(ii) KOOCN=NCOOK, AcOH/MeOH/THF (86%); (iii) HF-pyridine, pyri-
dine, THF (76%); (iv) LiOH·H2O, MeOH/THF/H2O (93%).
The 1H and 13C NMR spectra of all four acids were essen-
tially identical to those of a sample extracted from M. tuber-
culosis. The natural mixture was protected as the acetate on
the alcohol and a methyl ester ([α]D +3.7),27 as a mixture of
homologues in which 2 predominates. The specific rotation
of the synthetic material 2a, protected in the same way
([α]D +4.2) was close to that of the natural mixture. The spe-
cific rotation of the synthetic free acid 2a was [α]D +2.1; the
rotation is dominated by the chirality of the hydroxy acid
part of the molecule and not indicative of the chirality of
the cis-cyclopropanes, which contribute very little. Thus,
the three isomers prepared in this work showed specific ro-
tations of +2.0 (22), +2.5 (23) and +2.5 (24).
MA containing trans-cyclopropanes at the position in
the chain closest to the hydroxy-acid are reported to have a
particular effect on the cell wall and therefore on the sensi-
tivity of mycobacterial species to hydrophobic antibiotics.5
A purified trehalose ester of MA lacking trans-cyclopropane
rings is five times more potent in stimulating macrophages,
and is important as a suppressor of Mtb induced inflamma-
tion and virulence.10 The biosynthesis apparently involves
conversion of a cis-alkene into an α-methyl-trans-alkene
caused by MmaS1 and SAM. This is then cyclopropanated
by the CmaA2 gene, again with SAM, to give the α-methyl-
trans-cyclopropane.21–25 Inactivation of CmaA2 causes the
accumulation of unsaturated derivatives in both methoxy-
and keto-MA and the lack of trans-cyclopropanes.26 Al-
though α-MA containing a proximal trans-cyclopropane
and a distal cis-cyclopropane do not appear to be present in
Mtb, they are present in other Mycobacteria such as Myco-
bacterium kansasii and Mycobacterium avium complex.8
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C. Don Lawson et al. PaperSyn OpenWe therefore describe the synthesis of two stereoiso-
mers of one such compound. The aldehyde 2528 was cou-
pled to sulfone 27 (see the Supporting Information) in a
modified Julia–Kocienski reaction, followed by saturation of
the derived mixture of alkenes with di-imide to give 28, and
then oxidative cleavage of the acetal to produce the cis-
aldehyde 29. Treatment with base isomerised this to the
trans-cyclopropane aldehyde 30. The corresponding
aldehyde 31 was prepared by a similar sequence (Scheme 9).
Scheme 9  Reagents and conditions: (i) DEAD, Ph3P, 1-phenyl-1H-tetra-
zole-5-thiol (91%); (ii) H2O2, Mo7O24(NH4)6·4H2O, IMS/THF (87%); 
(iii) 25, LiHMDS, THF (78%); (iv) KOOCN=NCOOK, AcOH, MeOH, THF 
(84%); (v) HIO4, ether (83%); (vi) NaOMe, MeOH/THF, reflux, 56 h (77%).
Chain extension of the two aldehydes by standard
methods provided the aldehydes 33 and 34 (Scheme 10),
which were then coupled to sulfone 3535 to provide, after
hydrolysis of the protecting groups, the free MA 37 and 38
(Scheme 11).
Scheme 10  Reagents and conditions: (i) LiHMDS, 32, THF (94%); 
(ii) KOOCN=NCOOK, AcOH, MeOH, THF (73%); 
(iii) KOH, THF/MeOH/H2O (60%); (iv) PCC, CH2Cl2 (85%).
Scheme 11  Reagents and conditions: (i) LiHMDS, THF (85%); 
(ii) KOOCN=NCOOK, AcOH, MeOH, THF (83%); (iii) HF-pyridine com-
plex, pyridine (72%); (iv) LiOH, THF, MeOH, H2O (70%); (v) imidazole, 
TBDMSCl, 4-DMAP; K2CO3, THF, MeOH, H2O then K2HSO4 (85%).
The effects of the four stereoisomeric MAs 2a and 22–24
in stimulating T-cells have recently been reported. Rather
surprisingly, mycolic acid 24 is somewhat more stimulatory
than 2a, both having a somewhat stronger effect than 22,
with 23 having the least effect.36 The trans-cyclopropane 38
is moderately stimulatory, while 37 has a smaller effect.
MA are present both as bound tetramycolyl penta-arab-
inose clusters and as extractable trehalose 6,6′-dimycolates
(‘cord factor’).2–7 The MA 37 and 38 were converted into the
corresponding TDM and TMM (see the the Supporting In-
formation) using methods described before.37 The effects of
the resulting TDMs and TMMs, and those derived from acid
22 in activating bone marrow dendritic cells to produce
proinflammatory cytokines (IL-6 and TNF-α) and reactive
oxygen species has recently been reported.38 Moreover,
they are recognised by antibodies in the serum of patients
with pulmonary tuberculosis, providing the basis of a diag-
nostic assay.39
Chemicals used were obtained from commercial suppliers or pre-
pared from them by methods described. Solvents which had to be dry,
for example diethyl ether and tetrahydrofuran were dried over sodi-
um wire. Petroleum was of boiling point 40–60 °C. Reactions under
inert conditions were carried out under a slow stream of nitrogen. Re-
actions carried out at low temperatures were cooled using a bath of
methylated spirit with liquid nitrogen. Silica gel (Merck 7736 silica
gel) and silica plates used for thin-layer and column chromatography
were obtained from Aldrich. Organic solutions were dried over anhy-
drous magnesium sulfate. IR spectra were carried out with a Perkin–
Elmer 1600 FTIR spectrometer as liquid films. NMR spectroscopy was
carried out with Bruker Avance 400 or 500 spectrometers. [α]D values
were recorded in CHCl3 with a POLAAR 2001 Optical Activity po-
larimeter. Mass spectra were recorded with a Bruker-MALDI-TOF MS
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C. Don Lawson et al. PaperSyn Openinstrument (to an accuracy of 1 d. p.); accurate mass values were ob-
tained in Bangor with a Bruker Microtof LC-MS or by the EPSRC MS
service in Swansea or in Bristol University.
(1R,2S)-2-Eicosylcyclopropanecarbaldehyde (6)
(a) 5-(Nonadecyl-1-sulphonyl)-1-phenyl-1H-tetrazole 4 (15.0 g, 0.032
mol) and butyric acid (1R,2S)-(cis-2-formylcyclopropyl) methyl ester
5 (4.8 g, 0.282 mol)28 were dissolved in anhydrous THF (250 mL) and
cooled to –10 °C. LiHMDS (38.6 mL, 0.041 mol) was carefully added
and the mixture was stirred for 1.5 h, then water (100 mL) was added.
The aqueous layer was separated and extracted with petrol/ether
(1:1, 3 × 50 mL) and the combined organic layers were washed with
brine (2 × 100 mL), dried and evaporated to obtain a residue; column
chromatography, eluting with petrol/EtOAc (20:1) gave butyric acid
(E/Z)-(1R,2S)-cis-2-eicos-1-enylcyclopropyl-methyl ester (9.5 g, 80 %)
a colourless oil, as a mixture of isomers in ratio 2.5:1. The derived es-
ter (8.5 g, 0.020 mol) in THF (50 mL) was gradually added to a stirred
suspension of lithium aluminium hydride (1.3 g, 0.034 mol) in THF
(50 mL) placed in a cooling bath, in order to control the exothermic
reaction. The reaction was heated at reflux at 100 °C for 2 h, then
cooled and quenched with freshly prepared sat. aq. sodium sulfate
decahydrate (30 mL), stirred until a white precipitate was formed and
then filtered through a bed of Celite washing with THF (3 × 50 mL).
The filtrate was evaporated and the crude product was purified by
column chromatography eluting with petrol/EtOAc (5:2) to give (E/Z)-
(1R,2S)-cis-2-eicos-1-enylcyclo-propylmethanol (6.4 g, 90%) as a
thick colourless oil. Hydrazine hydrate (80 mL), glacial acetic acid (5
mL) and sat. aq. copper sulphate (5 mL) were added in succession to
the above alkenes (6.0 g, 0.017 mol) in 2-propanol (200 mL) at 70–
80 °C. Subsequently, sodium (meta)periodate (73.4 g, 0.343 mol) in
hot water was added dropwise over a period of 2 h, maintaining the
temperature at 70–80 °C. The reaction was stirred for 1 h at r.t. and
then quenched with sat. aq. ammonium chloride (100 mL). The aque-
ous layer was extracted with petrol/EtOAc (1:1, 3 × 150 mL) and the
combined organic layers were washed with brine, dried and evapo-
rated, and the product was recrystallised from petrol to give (1R,2S)-
2-eicosylcyclpropyl methanol.
Yield: 5.0 g (83%); white solid; mp 57–59 °C; [α]D26 +12 (c 1.1, CHCl3).
MS: m/z [M + Na]+ calcd for C24H48ONa: 375.3602; found: 375.3645.
1H NMR (500 MHz, CDCl3): δ = 3.65 (dd, J = 7.2, 11.0 Hz, 1 H), 3.58 (dd,
J = 7.9, 11.0 Hz, 1 H, ), 1.67 (br s, 1 H), 1.50–1.38 (m, 4 H), 1.32–1.2 (m,
35 H), 1.15–1.09 (m, 1 H), 0.88 (t, J = 6.9 Hz, 3 H), 0.69 (dt, J = 4.7,
8.2 Hz, 1 H), –0.01 (q, J = 5.2 Hz, 1 H)
13C NMR (126 MHz, CDCl3): δ = 63.5, 32.0, 30.5, 29.9, 29.8, 29.5, 28.6,
22.8, 18.5, 16.3, 14.0, 10.0.
IR: 3313, 1463, 1377, 1040, 1008, 720 cm–1.
(c) The above alcohol (5.0 g, 14 mmol) in dichloromethane (80 mL)
was added to a stirred suspension of pyridinium chlorochromate (7.6
g, 35 mmol, 2.5 mol equiv) in dichloromethane (200 mL) at r.t. The
mixture was stirred for 2 h at r.t., then diluted with ether/petrol 2:1
(300 mL), then filtered through a pad of silica and Celite, washed well
with ether (2 × 100 mL) and evaporated to give a white solid, which
was purified by column chromatography on silica eluting with pet-
rol/ether 2:1 to give the title compound 6.
Yield: 4.5 g (91%); [α]D26 +3.8 (c 1.1, CHCl3) (enantiomer –3.9 (c 1.1,
CHCl3)).28
1H NMR (500 MHz, CDCl3): δ = 9.37 (d, J = 5.4 Hz, 1 H), 1.89–1.83 (m,
1 H), 1.62–1.55 (m, 2 H), 1.53–1.46 (m, 2 H), 1.43–1.2 (m, 36 H), 1.19
(m, 1 H), 0.88 (t, J = 6.9 Hz, 3 H).
13C NMR (126 MHz, CDCl3): δ = 201.8, 31.9, 30.0, 29.7, 29.64, 29.6,
29.5, 29.4, 29.33, 29.3, 28.2, 27.8, 26.9, 24.8, 23.0, 22.7, 17.7, 14.8,
14.4, 14.1.
IR: 2921, 2851, 1700, 1465, 1215, 758, 470, 457, 441 cm–1.
13-((1R,2S)-cis-2-Eicosylcyclopropyl)tridecan-1-ol (8)
LiHMDS (18.2 mL, 19.3 mmol) was added to a stirred solution of
(1R,2S)-2-eicosylcyclopropanecarbaldehyde 6 (4.0 g, 11 mmol) and
2,2-dimethylpropanoic acid 12-(1-phenyl-1H-tetrazole-5-yl-sulfo-
nyl)dodecyl ester 7 (7.10 g, 14.9 mmol)40 in anhydrous THF (200 mL)
at –10 °C under nitrogen. The mixture was allowed to reach r.t.,
stirred for 2 h, then the reaction was quenched with sat. aq. ammoni-
um chloride (200 mL), the aqueous layer was separated and extracted
with petrol/ether (1:1, 3 × 200 mL). The combined organic layers were
dried and concentrated and the residue was purified by column chro-
matography, eluting with petrol/ether (20:1) to give 2,2-dimethylpro-
pionic acid (E/Z)-13-((1R,2S)-cis-2-eicosylcyclopropyl)tridec-12-enyl
ester (6.6 g, 98%) as a white solid, as a mixture of isomers in ratio (2.8
:1). The derived ester (6.0 g, 10 mmol) in THF (20 mL) was gradually
added to a stirred suspension of lithium aluminium hydride (0.77 g,
20 mmol) in THF (50 mL) at 0 °C. The mixture was heated at reflux at
100 °C for 2 h, then worked up and purified as before to give (E/Z)-13-
((1R,2S)-cis-2-eicoscylcyclopropyl)-tridec-12-en-1-ol (5.0 g, 91%) as a
white solid. Hydrazine monohydrate (20 mL), acetic acid (2 mL), and
sat. aq. copper sulfate (2 mL) were added in succession to the derived
alcohols (5.0 g, 9.7 mmol) in isopropanol (250 mL) at 80 °C, and then
sodium metaperiodate solution (20 g, 97 mmol) in hot water (60 mL)
was carefully added dropwise, maintaining the temperature at 80 °C,
then worked up as above. The product was recrystallised from chloro-
form to give the title compound 8.
Yield: 3.8 g (75%); mp 72–74 °C; [α]D26 –0.33 (c 2.03, CHCl3).
1H NMR (500 MHz, CDCl3): δ = 3.65 (t, J = 6.6 Hz, 2 H), 1.58 (pent, J =
6.65 Hz, 4 H), 1.40–1.22 (m, 57 H), 1.15–1.10 (m, 2 H), 0.89 (t, J =
6.6 Hz, 3 H), 0.65 (m, 2 H), 0.56 (dt, J = 4.0, 7.8 Hz, 1 H), –0.32 (q, J =
5.35 Hz, 1 H).
13C NMR (126 MHz, CDCl3): 63.1, 32.8, 32.0, 30.2, 29.7, 29.63, 29.6,
29.4, 29.3, 28.7, 25.7, 22.7, 15.8, 14.1, 10.9.
IR: 3383, 2917, 2848, 1465, 1064, 723, 449, 426, 417, 412 cm–1.
13-((1R,2S)-2-Eicosylcyclopropyl)tridecanal (9)
Alcohol 8 (4.5 g, 8.6 mmol) in dichloromethane (80 mL) was added to
a stirred suspension of PCC (4.66 g, 22.0 mmol, 2.5 mol equiv) in di-
chloromethane (60 mL) in portions at r.t. The mixture was stirred for
2 h and then diluted with petrol/ether 2:1 (300 mL), filtered through a
pad of Celite on silica, then washed well with warm ether (400 mL)
and the filtrate was evaporated to give a residue. This was purified by
column chromatography on silica eluting with petrol/ether 2:1 to give
the title compound 9.
Yield: 3.6 g (84%); mp 61–64 °C, [α]D22 +1.6 (c 1.2, CHCl3) (enantiomer
–1.7 (c 1.2, CHCl3)).28
1H NMR (500 MHz, CDCl3): 9.77 (t, J = 1.9 Hz, 1 H), 2.42 (br td, J = 1.9,
7.3 Hz, 2 H), 1.63 (pent, J = 6.9 Hz, 2 H), 1.38–1.12 (br m, 56 H), 1.15–
1.1 (m, 2 H), 0.88 (t, J = 6.9 Hz, 3 H), 0.67–0.61 (m, 2 H), 0.56 (td, J =
3.7, 7.8 Hz, 1 H), –0.32 (br q, J = 5.4 Hz, 1 H).
13C NMR (126 MHz, CDCl3): 203.0, 43.9, 31.9, 30.2, 29.6, 29.5, 29.4,
29.3, 29.2, 29.1, 28.7, 22.6, 22.0, 15.7, 14.1, 10.8.
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phenyl-1H-tetrazole (10)
(a) 13-((1R,2S)-cis-2-Eicosylcyclopropyl)tridecan-1-ol 8 (4.0 g, 7.7
mmol) was dissolved in anhydrous THF (10 mL) together with triph-
enylphosphine (2.6 g, 10 mmol) and 1-phenyl-1H-tetrazole-5-thiol
(1.8 g, 10 mmol). The mixture was cooled to 0 °C, followed by the ad-
dition of DEAD (1.7 mL, 10 mmol) in anhydrous THF (5 mL). The mix-
ture was stirred overnight at r.t., evaporated, then the residue was
washed with petrol/ether (10:1) and then filtered. The filtrate was
evaporated and the product was purified by column chromatography
eluting with chloroform to give 5-[13-((1R,2S)-cis-2-eicosylcyclopro-
pyl)tridecyl-sulfanyl]phenyl-1H-tetrazole.
Yield: 5.1 g (97%); mp 42–44 °C; [α]D22 –1.2 (c 1.3, CHCl3).
MS: m/z [M + Na]+ calcd for C43H76N4SNa: 703.5683; found: 703.5658.
1H NMR (500 MHz, CDCl3): δ = 7.62–7.52 (m, 5 H), 3.42 (t, J = 7.4 Hz,
2 H), 1.84 (pent, J = 7.5 Hz, 2 H), 1.47 (pent, J = 7.3 Hz, 2 H), 1.43–1.12
(m, 58 H), 0.91 (t, J = 6.9 Hz, 3 H), 0.71–0.64 (m, 2 H), 0.59 (dt, J = 4.1,
8.3 Hz, 1 H), –0.35 (q, J = 4.9 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 154.8, 134.2, 133.3, 130.1, 125.9, 33.7,
30.2, 29.7, 29.65, 29.6, 29.5, 29.43, 29.4, 29.1, 29.0, 28.73, 28.7, 22.9,
15.6, 14.4, 11.1.
IR: 1600, 1465, 1378, 1244, 1168, 1015, 693 cm–1.
(b) Sodium hydrogen carbonate (1.7 g, 20 mmol) was added to a
stirred solution of the above tetrazole (3.0 g, 4.4 mmol) in dichloro-
methane (50 mL), followed by the addition of a mixture of anhydrous
3-chloroperoxybenzoic acid (2.0 g, 88 mmol) and dichloromethane
(50 mL). The reaction was stirred at r.t. for 18 h to give an off-white
precipitate, then aq. sodium hydroxide (5%; 100 mL) was added and
the mixture was stirred for 2 h. The organic layer was separated and
the aqueous layer was extracted with dichloromethane (3 × 200 mL).
The combined organic layers were washed with water (2 × 200 mL),
dried and evaporated. The product was recrystallised from metha-
nol/acetone (1:1), which gave a white solid of the title compound 10.
Yield: 2.1 g (67%); mp 50–52 °C; [α]D22 +1.7 (c 1.4, CHCl3).
MS: m/z [M + Na]+ calcd for C43H76N4O2SNa: 735.5581; found:
735.5596.
1H NMR (500 MHz, CDCl3): δ = 7.72–7.70 (m, 5 H), 3.74 (distorted t, J =
8.0 Hz, 2 H), 1.96 (br pent, J = 7.8 Hz, 2 H), 1.50 (br pent, J = 7.4 Hz,
2 H), 1.45–1.10 (m, 58 H), 0.89 (t, J = 6.8 Hz, 3 H), 0.66–0.64 (m, 2 H),
0.57 (dt, J = 4.1, 8.5 Hz, 1 H), –0.33 (q, J = 4.8 Hz, 1 H).
13C NMR (125 MHz, CDCl3): δ = 154.5, 134.0, 133.4, 130.6, 126.1, 56.4,
31.9, 30.3, 29.7, 29.5, 29.48, 29.4, 29.2, 28.9, 28.7, 28.2, 22.8, 22.2,
16.1, 14.3, 11.0.
IR: 1764, 1597, 1464, 1377, 1357, 1218, 1147, 1013, 685, 633 cm–1.
((1R,2S)-2-(14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl)cyclopro-
pyl)methanol (12)
(a) LiHMDS (12.8 mL, 13 mmol, 1.06 M, 1.5 mol) was added dropwise
with stirring to aldehyde 9 (3.6 g, 6.9 mmol) and sulfone 11 (3.3 g, 7.5
mmol)32,33 in anhydrous THF (30 mL) under nitrogen at–10 to –4 °C.
The mixture was allowed to reach r.t., stirred for 5 h, then the reaction
was quenched with sat. aq. ammonium chloride (50 mL) and pet-
rol/ether 1:1 (100 mL). The organic layer was separated and the aque-
ous layer was re-extracted with petrol/ether 1:1 (2 × 100 mL). The
combined organic layers were dried and evaporated to give a solid;
column chromatography on silica eluting with petrol/ether 10:1 gave
a mixture of alkenes (3.0 g, 65 %).
(b) LiAlH4 (0.2 g) was added to stirred THF (100 mL) at 0 °C under ni-
trogen to ensure THF dryness. Then further LiAlH4 (1.0 g, 26 mmol)
was added. A solution of alkenes (3.0 g, 4.5 mmol) in anhydrous THF
(20 mL) was added dropwise by using a syringe at 0 °C and the mix-
ture was heated at reflux for 3 h, then cooled to 0 °C and the reaction
was quenched with sat. aq. sodium sulphate decahydrate (20 mL),
which was added dropwise and stirred at r.t until a white precipitate
was formed followed by addition of MgSO4 (20 g). THF (40 mL) was
added and the mixture was filtered through a pad of silica, dried and
the solvent evaporated to give a mixture of alcohols (2.4 g, 89%),
which was used for the next step without further purification.
(c) Sodium (meta)periodate (20.3 g, 95.0 mmol) in hot water (50 mL)
was added over 70 min at 70–80 °C to a stirred solution of above alco-
hol (2.9 g, 4.8 mmol) in isopropyl alcohol (250 mL), acetic acid (1.5
mL), sat. aq. copper sulphate (1.5 mL) and hydrazine hydrate (20 mL).
The mixture was stirred for 2 h until it reached r.t., then diluted with
water (100 mL) and petrol/ether 5:1 (400 mL). Due to the low solubil-
ity of the product, the mixture was warmed (40 °C) to allow separa-
tion. The aqueous layer was re-extracted with warm petrol/ether 5:1
(3 × 100 mL). The combined organic layers were dried and evaporated
to give a solid. Column chromatography on silica eluting with
petrol/ether 5:1 gave the title compound 12.
Yield: 1.8 g (63%); white solid; mp 72–74 °C; [α]D26 +8.3 (c 0.86,
CHCl3)
MS: m/z [M + H]+ calcd for C41H81O: 590.0978; found: 590.0980.
1H NMR (500 MHz, CDCl3): δ = 3.66 (dd, J = 7.3, 11 Hz, 1 H), 3.59 (dd,
J = 7.9, 11 Hz, 1 H), 1.56 (br m, 4 H), 1.47–1.20 (br m, 60 H), 1.17–1.05
(m, 4 H), 0.9–0.84 (including t at δ 0.88 with J = 6.95 Hz, 4 H), 0.70 (dt,
J = 4.4, 8.2 Hz, 1 H), 0.68–0.63 (m, 2 H), 0.57 (dt, J = 4.1, 8.5 Hz, 1 H),
–0.03 (q, J = 5.35 Hz, 1 H), –0.32 (q, J = 5.35 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 63.4, 31.9, 30.2, 30.18, 29.7, 29.65,
29.6, 29.4, 28.7, 28.6, 22.7, 18.2, 16.2, 15.8, 14.1, 10.9, 9.5.
IR: 3375, 2852, 1771, 1464, 1370, 1170, 1064, 1037, 964, 932, 823
cm–1.
(1S,2R)-2-[14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl]cyclopro-
pyl Methanol (14)
LiHMDS (3.7 mL, 4.0 mmol) was added to a stirred solution of butyric
acid (1S,2R)-(cis-2-formylcyclopropyl)methyl ester 13 (0.5 g 3.0
mmol) and sulfone 10 (2.1 g, 30 mmol) in anhydrous THF (30 mL) at
–10 °C. The mixture was allowed to reach r.t. and stirring was contin-
ued for 1.5 h, then worked up and purified as before to give butyric
acid (1S,2R)-2-[(E/Z)-14-((1R,2S)-2-eicosylcyclopropyl)tetradec-1-
enyl]cyclopropylmethyl ester (1.2 g, 62%) as a white solid as a mixture
in ratio 2.5:1. The above ester (1.2 g, 1.8 mmol) in THF (10 mL) was
added dropwise to a stirred suspension of lithium aluminium hydride
(0.14 g, 3.7 mmol) in THF (10 mL) at –10 °C under nitrogen atmo-
sphere. The reaction was heated at reflux at 100 °C for 2.5 h then
worked up as before to give (1S,2R)-2-[(E/Z)-14-((1R,2S)-2-eicosyl-
cyclopropyl)tetradec-1-enyl]cyclopropyl methanol (0.77 g, 72 %) as a
white solid. Hydrazine monohydrate (7 mL), acetic acid (1 mL), and
sat. aq. copper sulfate (1 mL) were added in succession at 70–80 °C to
a stirred solution of the above alcohol (0.77 g, 1.3 mmol) in isopropyl
alcohol (50 mL). Still maintaining the temperature at 80 °C, a solution
of sodium metaperiodate (2.8 g, 13 mmol) in hot water (10 mL) was
carefully added dropwise. The mixture was allowed to reach r.t. and
stirred for 1 h, then worked up as above to give the title compound 14.
Yield: 0.55 g (71%); white solid; mp 51–53 °C; [α]D21 –7.3 (c 1.0,
CHCl3).
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J = 8.0, 11.4 Hz, 1 H), 1.62–1.55 (m, 4 H), 1.45–1.2 (m, 60 H), 1.15–
1.05 (m, 4 H), 1.15–1.05 (m, 4 H), 0.92–0.83 (including t at δ 0.89 with
J = 6.8 Hz, 4 H), 0.72 (dt, J = 4.3, 8.3 Hz, 1 H), 0.69–0.63 (m, 2 H), 0.57
(dt, J = 4.1, 8.5 Hz, 1 H), –0.03 (q, J = 5.3 Hz, 1 H), –0.33 (q, J = 5.0 Hz,
1 H).
13C NMR (126 MHz, CDCl3): δ = 63.6, 32.2, 31.9, 30.2, 29.7 (very br),
29.4, 28.7, 22.9, 18.4, 16.2, 15.8, 14.2, 10.9, 9.47.
IR: 3368, 2852, 1771, 1464, 1370, 1170, 1064, 1037, 964, 932, 823
cm–1.
(1R,2S)-2-[14-((1S,2R)-2-Eicosylcyclopropyl)tetradecyl]cyclopro-
pyl Methanol (16)
LiHMDS (6.1 mL, 6.5 mmol) was added to a stirred solution of alde-
hyde 5 (0.85 g, 5.0 mmol) and sulfone 15 (3.6 g, 5.0 mmol) (see the
Supporting Information) in anhydrous THF (50 mL) at –10 °C. The re-
action mixture was worked up as before to give butyric acid (1R,2S)-
2-[(E/Z)-14-((1S,2R)-2-eicosylcyclopropyl)tetradec-1-enyl]cyclopro-
pylmethyl ester (2.5 g, 78%) as a white solid. Lithium aluminium hy-
dride (0.29 g, 7.62 mmol) in THF (20 mL) was reacted with the ester
(2.5 g, 3.8 mmol) in THF (20 mL). Work up as before gave (1R,2S)-2-
[(E/Z)-14-((1S,2R)-2-eicosylcyclopropyl)tetradec-1-enyl]cyclopropyl-
methanol (1.1 g, 50%). Hydrazine monohydrate (10 mL), acetic acid (1
mL) and sat. aq. copper sulfate (1 mL) were added in succession to the
unsaturated alcohols (1.1 g, 1.9 mmol) in isopropanol (30 mL), and
the mixture was treated with sodium metaperiodate (4.0 g, 18.8
mmol) in hot water (10 mL) at 80 °C. The reaction was worked up as
before and the product was extracted with petrol/ether (1:1, 3 × 50
mL), then recrystallised from petrol to give a (1R,2S)-2-[14-((1S,2R)-
2-eicosylcyclopropyl)tetradecyl]cyclopropylmethanol 16.
Yield: 0.7 g (63%); white solid; mp 59–61 °C; [α]D21 +7.6 (c 1.2, CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C41H80ONa: 611.6; found: 611.9.
1H NMR (500 MHz, CDCl3): δ = 3.7 (dd, J = 7.5, 11.5 Hz, 1 H), 3.59 (dd,
J = 8.0, 11.5 Hz, 1 H), 1.62–1.55 (m, 4 H), 1.45–1.2 (m, 60 H), 1.15–
1.05 (m, 4 H), 0.92–0.83 (including t at δ 0.89 with J = 6.8 Hz, 4 H),
0.73 (dt, J = 4.5, 8.4 Hz, 1 H), 0.68–0.63 (m, 2 H), 0.58 (dt, J = 4.1,
8.5 Hz, 1 H), –0.03 (q, J = 5.5 Hz, 1 H), –0.33 (q, J = 5.0 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 63.8, 32.4, 31.9, 30.2, 29.7 (very
broad), 29.4, 28.7, 22.9, 18.6, 16.2, 15.8, 14.2, 10.9, 9.47.
IR: 3365, 2850, 1770, 1462, 1370, 1169, 1062, 1035, 963, 930, 821
cm–1.
5-(((1R,2S)-2-(14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl)cyclo-
propyl)methylsulfonyl)-1-phenyl-1H-tetrazole (17)
(a) Alcohol 12 (1.7 g, 2.9 mmol) was dissolved in anhydrous THF (50
mL) together with triphenylphosphine (1.14 g, 4.3 mmol, 1.5 equiv)
and 1-phenyl-1H-tetrazole-5-thiol (0.82 g, 4.6 mmol, 1.6 equiv). The
mixture was cooled to 0 °C, followed by the addition of DEAD (0.82 g,
4.0 mmol, 1.4 equiv) in anhydrous THF (5 mL). The mixture was
stirred at r.t. overnight. The solvent was evaporated to a small volume
to which petrol/ether 1:1 (100 mL) was added and the mixture was
stirred at r.t. for 45 min, then filtered. The filtrate was dried and evap-
orated to give a solid. Column chromatography on silica eluting with
petrol/ether 10:2 gave 5-[(1R,2S)-2-[14-((1R,2S)-2-eicosylcyclopro-
pyl)tetradecyl]cyclopropylmethyl-sulfanyl]-1-phenyl-1H-tetrazole.
Yield: 2.0 g (93%); [α]D26 +3.2 (c 1.3, CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C48H84N4SNa: 771.6; found: 771.5.
1H NMR (500 MHz, CDCl3): δ = 7.65–7.5 (m, 5 H), 3.49 (d, J = 7.9 Hz,
2 H), 1.56 (br s, 3 H), 1.49 (m, 1 H), 1.38–1.13 (br m, 63 H), 0.95–0.9
(m, 1 H), 0.88 (t, J = 7.3 Hz, 3 H), 0.83 (dt, J = 5.1, 8.5 Hz, 1 H), 0.67–
0.62 (m, 2 H), 0.56 (dt, J = 4.1, 8.2 Hz, 1 H), 0.08 (q, J = 5.4 Hz, 1 H),
–0.32 (q, J = 5.4 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 154.6, 133.8, 132.1, 130.0, 129.7,
128.5, 128.4, 128.4, 123.8, 35.0, 31.9, 30.2, 30.0, 29.7, 29.65, 29.5,
28.7, 28.5, 22.7, 18.0, 15.8, 14.6, 14.1, 12.5, 10.9.
IR: 3068, 2988, 2916, 2849, 1599, 1502, 1469, 1381, 1234, 1016, 824,
754, 694, 542, 458, 451, 435 cm–1 .
(b) Sodium hydrogen carbonate (1.03 g, 12 mmol, 4.5 equiv) was add-
ed to a stirred solution of the above tetrazole (2.0 g, 2.7 mmol) in di-
chloromethane (100 mL), followed by the addition of a mixture of an-
hydrous 3-chloroperoxybenzoic acid 70% (1.67 g, 9.7 mmol, 2.5
equiv) in CH2Cl2 (50 mL). The reaction was stirred at r.t. for 48 h to
give an off-white precipitate. Aq. sodium hydroxide (5%, 80 mL) was
added and the aqueous layer was extracted with dichloromethane
(3 × 200 mL). The combined organic layers were washed with water
(2 × 200 mL), dried and evaporated. The product was recrystallised
from methanol/acetone (1:1), to give the title compound 17.
Yield: 1.77 g (85%); [α]D20 –18 (c 1.5, CHCl3).
MS: m/z [M + H]+ calcd for C48H85N4O2S: 782.2976; found: 782.2980.
1H NMR (500 MHz, CDCl3): δ = 7.72–7.68 (m, 2 H), 7.65–7.58 (m, 3 H),
3.98 (dd, J = 5.35, 14.5 Hz, 1 H), 3.57 (dd, J = 9.15, 14.5 Hz, 1 H), 1.5–
1.2 (m, 66 H), 1.17–1.1 (m, 1 H), 1.03–0.94 (m, 1 H), 0.90–0.86 (in-
cluding t at δ 0.89 with J = 6.95 Hz, 4 H), 0.68–0.64 (m, 2 H), 0.56 (dt,
J = 4.1, 8.2 Hz, 1 H), 0.25 (q, J = 5.7 Hz, 1 H), –0.32 (q, J = 5.35 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 153.7, 133.1, 131.4, 129.7, 125.2, 57.1,
31.9, 30.2, 29.64, 29.6, 29.44, 29.4, 29.1, 28.7, 22.7, 15.9, 15.8, 14.1,
11.4, 10.9, 8.0.
IR: 2990, 2916, 2849, 1498, 1470, 1340, 1152, 761, 718, 687 cm–1.
5-[(1S,2R)-2-[14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl]cyclo-
propylmethanesulfonyl]-1-phenyl-1H-tetrazole (18)
(a) Alcohol 14 (0.55 g, 0.85 mmol) was dissolved in anhydrous THF (5
mL) and then triphenylphosphine (0.30 g, 1.1 mmol) and 1-phenyl-
1H-tetrazole-5-thiol (0.2 g, 1.1 mmol) were added. The mixture was
cooled to 0 °C and treated as above with DEAD (0.18 mL, 1.1 mmol) in
anhydrous THF (5 mL). After stirring at r.t. overnight, the reaction
mixture was worked up as above. Column chromatography eluting
with dichloromethane gave 5-[(1S,2R)-2-[14-((1R,2S)-2-eicosylcyclo-
propyl)tetradecyl]cyclopropylmethyl-sulfanyl]-1-phenyl-1H-tetra-
zole.
Yield: 0.7 g (92 %); mp 43–50 °C; [α]D20 –2.1 (c 1.7, CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C48H84N4SNa: 771.6; found: 771.4.
1H NMR (500 MHz, CDCl3): δ = 7.63–7.55 (m, 5 H), 3.49 (d, J = 7.9 Hz,
2 H), 1.60–1.11 (including m at 1.47–1.53 for one cyclopropane pro-
ton, 67 H), 0.95–0.9 (m, 1 H), 0.89 (t, J = 6.9 Hz, 3 H), 0.84 (dt, 4.7, 1 H,
8.2 Hz), 0.67–0.63 (m, 2 H), 0.57 (dt, J = 3.4, 8.2 Hz, 1 H), 0.08 (q, J =
5.4 Hz, 1 H), –0.32 (q, J = 5.4 Hz, 1 H).
13C NMR (125 MHz, CDCl3): δ = 133.8, 130, 123.8, 35.0, 31.9, 30.9,
29.5, 28.5, 22.7, 21.0, 18.0, 15.8, 14.6, 14.1, 12.
IR: 3059, 2923, 1463, 1340, 1275, 1169, 1088 cm–1.
(b) Ammonium molybdate(VI) tetrahydrate (2.90 g, 2.34 mmol) was
dissolved in cold hydrogen peroxide (35% w/w, 10 mL) and was added
gradually to a stirred solution of the above tetrazole (0.35 g, 0.47
mmol) in IMS/THF (30:10 mL) at 5–10 °C, then allowed to attain r.t.
and stirred for another 2 h after which further ammoniumGeorg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 103–116
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oxide (5 mL) was added. The reaction was stirred for 18 h and then
poured into water (200 mL) and extracted with dichloromethane
(3 × 50 mL). The organic layers were washed with water (2 × 50 mL)
and concentrated. Column chromatography eluting with petrol/ether
(5:2) gave the title compound 18.
Yield: 0.15 g (41%); mp 68–69 °C; [α]D20 +17 (c 1.2, CHCl3).
MS MALDI: m/z [M + Na]+ calcd for C48H84O2N4SNa: 803.6; found:
803.5.
1H NMR (500 MHz, CDCl3): δ = 7.72–7.68 (m, 2 H), 7.65–7.58 (m, 3 H),
3.98 (dd, J = 5.7, 14.9 Hz, 1 H), 3.57 (dd, J = 9.5, 14.9 Hz, 1 H), 1.38–
1.13 (m, 68 H), 1.05–0.97 (m, 1 H), 0.89 (t, J = 6.6 Hz, 3 H), 0.67–0.63
(m, 2 H), 0.57 (dt, J = 4.1, 8.2 Hz, 1 H), 0.08 (q, J = 5.6 Hz, 1 H), –0.33 (,
J = 5.0 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 131.4, 129.7, 125.2, 57.1, 31.9, 30.2,
29.7, 29.5, 29.1, 28.7, 22.7, 15.9, 14.1, 11.4, 10.9, 8.0.
IR: 2923, 2854, 1462, 1377, 1338, 1156 cm–1.
5-[(1R,2S)-2-[14-((1S,2R)-2-Eicosylcyclopropyl)tetradecyl]cyclo-
propylmethanesulfonyl]-1-phenyl-1H-tetrazole (19)
(a) Alcohol 16 (0.70 g, 1.2 mmol) was dissolved in anhydrous THF (5
mL) together with triphenylphosphine (0.41 g) and 1-phenyl-1H-
tetrazole-5-thiol (0.28 g, 1.55 mmol). The mixture was cooled to 0 °C,
followed by the addition of DEAD (0.24 mL, 1.55 mmol) in anhydrous
THF (5 mL), and then stirred overnight at r.t. Work up as above fol-
lowed by column chromatography eluting with dichloromethane gave
the sulfane.
Yield: 0.8 g (89%); mp 43–50 °C; [α]D20 +1.5 (c 1.4, CHCl3).
MS: m/z [M + Na]+ calcd for C48H84N4SNa: 771.6314; found: 771.6308.
1H NMR (500 MHz, CDCl3): δ = 7.62–7.54 (m, 5 H), 3.50 (d, J = 8.0 Hz,
2 H), 1.60–1.10 (including m at 1.46–1.51 for one cyclopropane pro-
ton, 67 H), 0.92–0.97 (m, 1 H), 0.89 (t, J = 6.6 Hz, 3 H), 0.83 (dt, 4.7,
8.1 Hz, 1 H), 0.68–0.63 (m, 2 H), 0.57 (dt, J = 3.8, 7.9 Hz, 1 H), 0.23 (q,
J = 5.4 Hz, 1 H), –0.33 (q, J = 5.4 Hz, 1 H).
13C NMR (125 MHz, CDCl3): δ = 133.8, 129.9, 123.8, 35.0, 31.9, 30.1,
29.5, 28.7, 22.7, 17.9, 15.8, 14.6, 14.1, 12.5, 10.9.
IR: 3059, 2920, 1463, 1339, 1275, 1169, 1088, 1018 cm–1.
(b) Ammonium molybdate(VI) tetrahydrate (5.0 g, 4.0 mmol) was dis-
solved in cold hydrogen peroxide (35%,w/w, 10 mL), and added gradu-
ally to a stirred mixture of the above sulfane (0.60 g, 0.80 mmol) in
IMS/THF (30:10 mL) at 5–10 °C. The reaction was stirred at r.t. for 2 h,
then more ammonium molybdate(VI) tetrahydrate (2.0 g, 1.6 mmol)
in cold hydrogen peroxide (5 mL) was added. The reaction was stirred
for 18 h and then poured into water (200 mL) and extracted with di-
chloromethane (3 × 50 mL). The organic layers were washed with
more water (2 × 50 mL), dried and concentrated. Column chromato-
graphy eluting with petrol/ether (5:2) gave 19.
Yield: 0.2 g (46%); whitish solid; mp 65–66 °C; [α]D20 –18 (c 1.4,
CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C48H84O2N4SNa: 803.6; found:
803.4.
1H NMR (500 MHz, CDCl3): δ = 7.72–7.68 (m, 2 H), 7.65–7.58 (m, 3 H),
3.98 (dd, J = 5.7, 14.9 Hz, 1 H), 3.57 (dd, J = 9.2, 14.9 Hz, 1 H), 1.38–
1.18 (m, 68 H), 1.05–0.97 (m, 1 H), 0.89 (t, J = 6.7 Hz, 3 H), 0.67–0.63
(m, 2 H), 0.57 (dt, J = 4.1, 8.2 Hz, 1 H), 0.08 (q, J = 5.6 Hz, 1 H), –0.33 (q,
J = 5.0 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 131.4, 129.7, 125.2, 57.1, 31.9, 30.2,
29.7, 29.5, 29.1, 28.7, 22.7, 15.9, 14.1, 11.4, 10.9, 8.0.
IR: 2922, 2852, 1464, 1377, 1339, 1156 cm–1.
(R)-2-((R)-1-(tert-Butyldimethylsilanyloxy)-12-{(1R,2S)-2-[14-
((1R,2S)-2-eicosylcyclopropyl)tetradecyl]cyclopropyl}do-
decyl)hexacosanoic Acid Methyl Ester (21)
(a) LiHMDS (2.78 mL, 2.9 mmol, 1.3 mol equiv, 1.06 M) was added to a
stirred solution of sulfone 17 (1.77 g, 2.27 mmol) and aldehyde 20
(1.77 g, 2.5 mmol, 1.1 mol equiv) in anhydrous THF (40 mL) at –10 °C
under nitrogen. The solution was allowed to reach r.t., stirred for 2 h,
then petrol/ether 10:1 (100 mL) and sat. aq. NH4Cl (50 mL) were add-
ed. The organic layer was separated and the aqueous layer was re-
extracted with petrol/ether 10:1 (2 × 100 mL). The combined organic
layers were dried and evaporated. Column chromatography eluting
with petrol/ether 20:1 gave the product alkenes (2.5 g, 87%) as an E/Z-
mixture in ratio 2.5:1.
(b) Dipotassium azodicarboxylate (3.0 g, 0.015 mol) was added to a
stirred solution of the above alkenes (2.4 g, 1.9 mmol) in anhydrous
THF (20 mL) and MeOH (25 mL) and then cooled to 0 °C. Then acetic
acid (5 mL) in THF (5 mL) was added dropwise at a rate of 1 mL/15
min. The reaction turned bright-yellow and was left stirring for 9 h at
5 °C. The procedure was repeated as above with further dipotassium
azodicarboxylate, acetic acid, stirring for a further 9 h, then quenched
by adding the mixture in small portions to sat. aq. NaHCO3 (50 mL).
After extraction, column chromatography eluting with petrol/ether
20:1 gave the title compound 21.
Yield: 2.07 g (86%); [α]D28 +3.8 (c 1.40, CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C85H168O3SiNa: 1288.3; found:
1288.4.
1H NMR (500 MHz, CDCl3): δ = 3.95–3.88 (m, 1 H), 3.7 (s, 3 H), 2.54
(ddd, J = 2.9, 6.4, 9.2 Hz, 1 H), 1.58–1.10 (m, 134 H), 0.87 (t J = 6.7 Hz,
6 H), 0.86 (s, 9 H), 0.68–0.62 (m, 4 H), 0.58 (dt, J = 3.8, 7.9 Hz, 2 H),
0.05 (s, 3 H), 0.03 (s, 3 H), –0.32 (q, J = 4.75 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 175.1, 73.2, 51.6, 51.2, 41.4, 36.1,
33.74, 33.7, 32.0, 30.3, 29.9, 29.74, 29.7, 29.65, 29.6, 29.5, 29.4, 28.9,
28.8, 27.9, 27.7, 27.5, 25.8, 23.7, 22.7, 22.6, 20.5, 19.4, 18.0, 15.8, 14.1,
10.9, –4.4, –4.9.
IR: 2923, 2853, 1742, 1465, 1253 cm–1.
(R)-2-((R)-1-Hydroxy-12-{(1R,2S)-2-[14-((1R,2S)-2-eicosylcyclo-
propyl)tetradecyl]cyclopropyl}dodecyl)hexacosanoic Acid (22)
(a) A dry polyethylene vial equipped with an acid-resistant rubber
septum was charged with the above TBDMS methyl ester (1.9 g, 1.5
mmol) and anhydrous pyridine (2 mL) in anhydrous THF (25 mL) and
stirred at r.t. under argon. To it was added hydrogen fluoride-pyridine
complex as ca. 70% hydrogen fluoride (3 mL) at 5 °C. The mixture was
then stirred at 45 °C for 17 h. The mixture was diluted with pet-
rol/ether 10:1 (100 mL) and neutralised by pouring it slowly into sat.
aq. sodium bicarbonate until no more CO2 was liberated. The product
was extracted with warm petrol/ether 10:1 (2 × 100 mL), and the
combined organic layers were washed with brine (100 mL). The or-
ganic layer was dried and evaporated to give a residue, which was pu-
rified by chromatography eluting with petrol/ether 10:1 to give
methyl (R)-2-((R)-1-hydroxy-12-{(1R,2S)-2-[14-((1R,2S)-2-eicosyl-
cyclopropyl)tetradecyl]cyclopropyl}dodecyl)hexacosanoate.
Yield: 1.32 g (76%); [α]D32 +4.3 (c 0.94, CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C79H154O3Na: 1175.0; found:
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(dt, J = 5.4, 9.5 Hz, 1 H), 1.72–1.14 (m, 135 H), 0.88 (t, 6 H, J = 6.95 Hz),
0.68–0.62 (m, 4 H), 0.57 (dt, J = 4.1, 8.6 Hz, 2 H), –0.32 (q, J = 4.8 Hz,
2 H).
13C NMR (126 MHz, CDCl3): δ = 176.2, 72.3, 51.5, 50.9, 35.7, 31.9, 30.2,
29.7, 29.66, 29.63, 29.6, 29.56, 29.55, 29.5, 29.42, 29.4, 28.7, 27.4,
25.7, 22.7, 15.8, 14.1, 10.9.
IR: 3400, 3016, 2905, 2858, 1463, 1199, 669 cm–1.
(b) The above methyl ester (1.0 g, 0.9 mmol) was dissolved in THF (15
mL), MeOH (1 mL) and water (1.5 mL), and then lithium hydroxide
monohydrate (1.10 g, 26.2 mmol, 30 equiv) was added to the stirred
mixture at r.t. The reaction was heated at 45 °C for 18 h, then cooled
to r.t. and diluted with petrol/EtOAc (7:2, 100 mL), followed by the
dropwise addition of sat. aq. potassium hydrogen sulfate (20 mL),
which brought the mixture to pH 1. The aqueous layer was separated
and re-extracted with warm petrol/EtOAc (7:2, 3 × 100 mL). The com-
bined organic layers were dried and concentrated to give a crude
product, which was purified by column chromatography, eluting with
warm petrol/EtOAc (7:2) to give compound 22.
Yield: 0.92 g (93%); Rf 0.42 (above solvent); [α]D24 +2.0 (c 1.2, CHCl3).
MS: m/z [M + Na]+ calcd for C78H152O3Na: 1161.06; found: 1160.59.
1H NMR (500 MHz, CDCl3): δ = 3.75–3.70 (m, 1 H), 2.44 (dt, J = 5.1,
8.8 Hz, 1 H), 1.74–1.14 (m, 136 H), 0.88 (t, J = 7.0 Hz, 6 H), 0.68–0.62
(m, 4 H), 0.57 (dt, J = 4.1, 8.6 Hz, 2 H), –0.32 (q, J = 5.1 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 182.1, 72.2, 50.8, 35.5, 31.9, 30.2, 29.7,
29.66, 29.6, 29.55, 29.42, 29.4, 28.7, 27.3, 25.7, 22.7, 15.8, 14.1, 10.9.
IR: 3427, 3019, 2916, 2848, 1467, 1215, 759, 669 cm–1.
(R)-2-((R)-1-Hydroxy-12-[(1S,2R)-2-[14-((1R,2S)-2-eicosylcyclo-
propyl)tetradecyl]cyclopropyl]dodecyl)hexacosanoic Acid (23)
(a) LiHMDS (0.30 mL, 0.24 mmol) was added to a stirred solution of
aldehyde 20 (0.12 g, 0.17 mmol) and tetrazole 18 (0.15 g, 0.19 mmol)
in anhydrous THF (5 mL) at –10 °C under nitrogen, then stirred for 1.5
h at r.t. Water (10 mL) was added and the mixture was extracted with
petrol/ether (1:1, 3 × 10 mL) and the combined organic layers were
washed with brine (2 × 10 mL), dried and filtered. The filtrate was
concentrated and the residue purified by column chromatography,
eluting with petrol/EtOAc (20:1), to give (R)-2-((E/Z)-(R)-1-(tert-bu-
tyldimethylsilanyloxy)-12-[(1S,2R)-2-[14-((1R,2S)-2-eicosylcyclopro-
pyl)tetradecyl]cyclopropyl]dodec-11-enyl)hexacosanoic acid methyl
ester (0.12 g, 49%).
(b) Dipotassium azodicarboxylate (2.0 g, 10 mmol) was added to a
stirred solution of the derived esters (0.11 g, 0.09 mmol) in anhydrous
THF (3 mL) and MeOH (1.5 mL) and then cooled to 0 °C under nitro-
gen. Glacial acetic acid (0.5 mL) was dissolved in THF (1.0 mL), and
then added dropwise to the reaction mixture, which was stirred over-
night at r.t. The process was repeated using the same amount of gla-
cial acetic acid in THF until there was a change in colour from bright
yellow to off-white. Work up as above gave a very thick oil of the cor-
responding TBDMS methyl ester.
Yield: 0.1 g (90%).
MS: m/z [M + Na]+ calcd for C85H168O3SiNa: 1288.3; found: 1288.6.
1H NMR (500 MHz, CDCl3): δ = 3.89 (td, J = 4.8, 6.6 Hz, 1 H), 3.64 (s,
3 H), 2.51 (ddd, J = 3.8, 7.2, 11.1 Hz, 1 H), 1.55–1.24 (m, 134 H), 0.85
(t, J = 7.0 Hz, 6 H), 0.84 (s, 9 H), 0.65–0.62 (m, 4 H), 0.55 (dt, J = 3.5,
7.9 Hz, 2 H), 0.05 (, 3 H), 0.02 (s, 3 H),–0.35 (q, J = 5.0 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 175.1, 73.2, 51.4, 33.7, 31.9, 30.2, 29.8,
29.7, 29.67, 29.62, 29.5, 29.45, 29.4, 28.7, 27.4, 25.8, 23.7, 22.7, 18.0,
15.8, 14.1, 10.9, –4.3, –4.9.
IR: 2923, 2853, 1742, 1464, 1254 cm–1.
(c) A dry polyethylene vial equipped with an acid-resistant rubber
septum was charged with the above TBDMS methyl ester (0.10 g, 0.08
mmol) and anhydrous pyridine (0.1 mL) in anhydrous THF (4 mL) and
stirred at r.t. under nitrogen. To it was added hydrogen fluoride-pyri-
dine complex as ca. 70% hydrogen fluoride (0.7 mL) at 5 °C. The mix-
ture was stirred at 45 °C for 17 h, then worked up and purified as
above to give (R)-2-((R)-1-hydroxy-12-[(1S,2R)-2-[14-((1R,2S)-2-
eicosylcyclopropyl)tetradecyl]cyclopropyl]dodecyl)hexacosanoic acid
methyl ester.
Yield: 0.03 g (33%); white solid; mp 55–57 °C; [α]D19 +2.5 (c 1.7,
CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C79H154O3Na: 1174.2; found:
1174.4.
1H NMR (500 MHz, CDCl3): δ = 3.71 (s, 3 H), 3.68–3.62 (m, 1 H), 2.46–
2.42 (m, 1 H), 1.74–1.70 (m, 1 H), 1.61–1.57 (m, 2 H), 1.48–1.15 (m,
132 H,), 0.89 (t, J = 6.6 Hz, 6 H), 0.68–0.62 (m, 4 H), 0.55 (dt, J = 4.1,
8.2 Hz, 2 H), –0.33 (q, J = 4.9 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 176.2, 72.3, 51.2, 35.7, 31.9, 30.2, 29.7,
29.65, 29.6, 29.5, 29.4, 29.36, 28.7, 27.4, 25.7, 22.7, 15.8, 14.1, 10.9.
IR: 3520, 2924, 2855, 2367, 1712, 1461, 1377, 1165, 721 cm–1.
(d) The above methyl ester (0.030 g, 0.026 mmol) was dissolved in
THF (4.0 mL), MeOH (0.5 mL) and water (0.7 mL), and then lithium hy-
droxide monohydrate (0.02 g, 0.48 mmol) was added to the stirred
mixture at r.t. The mixture was heated at 45 °C for 18 h, then cooled
to r.t. and diluted with petrol/EtOAc (7:2, 5 mL), followed by the drop-
wise addition of sat. aq. potassium hydrogen sulfate (10 mL) to pH 1.
The aqueous layer was extracted with warm petrol/EtOAc (7:2,
3 × 10 mL). The combined organic layers were dried and concentrat-
ed. Column chromatography, eluting with petrol/EtOAc (7:2) gave the
title compound 23.
Yield: 0.019 g (64%); white solid; mp 51–53 °C; Rf 0.42 (above sol-
vent); [α]D21 +2.5 (c 1.4, CHCl3).
MS: m/z [M + Na]+ calcd for C78H152O3Na: 1160.1634; found:
1160.1626.
1H NMR (500 MHz, CDCl3): δ = 3.73 (td, J = 4.8, 7.9 Hz, 1 H), 2.48 (td,
J = 5.4, 8.9 Hz, 1 H), 1.76–1.71 (m, 1 H), 1.63–1.60 (m, 2 H), 1.54–1.47
(m, 4 H), 1.26 (m, 129 H), 0.89 (t, J = 6.9 Hz, 6 H), 0.66–0.62 (m, 4 H),
0.57 (dt, J = 4.1, 8.2 Hz, 2 H), –0.33 (q, J = 4.9 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 178.6, 72.1, 50.8, 36.6, 31.9, 30.2, 29.7,
29.6, 29.5, 29.4, 28.7, 27.3, 25.7, 22.7, 15.8, 14.1, 10.9.
IR: 3281, 2919, 2852, 1709, 1466, 1377, 721 cm–1.
(R)-2-((R)-1-Hydroxy-12-[(1R,2S)-2-[14-((1S,2R)-2-eicosylcyclo-
propyl)tetradecyl]cyclopropyl]dodecyl)hexacosanoic Acid (24)
(a) LiHMDS (0.32 mL, 0.34 mmol) was added to a stirred solution of
aldehyde 20 (0.17 g, 0.24 mmol) and sulfone 19 (0.20 g, 0.26 mmol) in
anhydrous THF (5 mL) at –10 °C under nitrogen, then stirred at r.t. for
1.5 h. Water (10 mL) was added and the mixture was extracted with
petrol/ether (1:1, 3 × 10 mL) and the combined organic layers were
washed with sat. aq. sodium hydroxide (2 × 5 mL), and concentrated.
Column chromatography, eluting with petrol/EtOAc (20:1), gave (R)-
2-((E/Z)-(R)-1-(tert-butyldimethylsilanyloxy)-12-[(1S,2R)-2-[14-((1R,2S)-
2-eicosylcyclopropyl)tetradecyl]cyclopropyl]dodec-11-enyl)hexaco-
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stirred solution of the derived alkenes (0.11 g, 0.09 mmol) in anhy-
drous THF (3 mL) and MeOH (1.5 mL) and then cooled to 0 °C under
nitrogen. Glacial acetic acid (0.5 mL) was dissolved in THF (1.0 mL),
and then added dropwise to the mixture, which was stirred overnight
at r.t. The process was repeated using the same amount of glacial ace-
tic acid in THF until there was a change in colour from bright yellow
to off-white. The reaction was worked up and purified as before to
give (R)-2-(R)-2-((R)-1-(tert-butyldimethylsilanyloxy)-12-[(1R,2S)-2-
[14-((1S,2R)-2-eicosylcyclopropyl)tetradecyl]cyclopropyl]do-
decyl)hexacosanoic acid methyl ester.
Yield: 0.1 g (90 %); thick oil.
MALDI MS: m/z [M + Na]+ calcd for C85H168O3SiNa: 1288.3; found:
1288.5.
1H NMR (500 MHz, CDCl3): δ = 3.85 (td, J = 4.8, 6.5 Hz, 1 H), 3.66 (s,
3 H), 2.54 (ddd, J = 3.8, 7.3, 10.8 Hz, 1 H), 1.56–1.14 (m, 134 H), 0.89
(t, J = 6.6 Hz, 6 H), 0.85 (s, 9 H), 0.66–0.65 (m, 4 H), 0.55 (dt, J = 4.1,
8.2 Hz, 2 H), 0.05 (s, 3 H), 0.03 (s, 3 H), –0.33 (q, J = 4.9 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 175.1, 73.3, 51.4, 33.7, 31.9, 30.2, 29.8,
29.7, 29.67, 29.6, 29.5, 29.4, 28.7, 27.8, 25.8, 23.7, 22.7, 18.0, 15.8,
14.1, 10.9, –4.3, –4.9.
IR: 2924, 2853, 1742, 1465, 1254 cm–1.
(c) A dry polyethylene vial equipped with an acid-resistant rubber
septum was charged with the above ester (0.1 g, 0.08 mmol) and an-
hydrous pyridine (0.1 mL) in anhydrous THF (4 mL) and stirred at r.t.
under nitrogen. To it was added hydrogen fluoride-pyridine complex
(ca. 70% hydrogen fluoride, 0.7 mL) at 5 °C. The mixture was then
stirred at 45 °C for 17 h, then diluted with petrol/ether 10:1 (30 mL)
and worked up as before to give (R)-2-((R)-1-hydroxy-12-[(1R,2S)-2-
[14-((1S,2R)-2-eicosylcyclopropyl)tetradecyl]cyclopropyl]do-
decyl)hexacosanoic acid methyl ester.
Yield: 0.04 g (44%); white solid; mp 55–57 °C; [α]D19 +2.4 (c 2.0,
CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C79H154O3Na: 1174.2; found:
1174.4.
1H NMR (500 MHz, CDCl3): δ = 3.72 (s, 3 H), 3.68–3.62 (m, 1 H), 2.46–
2.41 (m, 1 H), 1.75–1.68 (m, 1 H), 1.62–1.57 (m, 2 H), 1.49–1.14 (m,
132 H,), 0.88 (t, J = 7.3 Hz, 6 H), 0.68–0.62 (m, 4 H), 0.58 (dt, J = 3.8,
8.1 Hz, 2 H), –0.33 (q, J = 5.0 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 176.2, 72.3, 51.2, 35.7, 31.9, 30.2, 29.7,
29.6, 29.5, 29.4, 29.3, 28.7, 27.4, 25.7, 22.7, 15.8, 14.1, 10.9.
IR: 3520, 2924, 2855, 2367, 1712, 1461, 1377, 1165, 721 cm–1.
(d) The above methyl ester (0.040 g, 0.035 mmol) was dissolved in
THF (4.0 mL), MeOH (0.5 mL) and water (0.7 mL), and then lithium hy-
droxide monohydrate (0.02 g, 0.48 mmol) was added with stirring at
r.t. The reaction was heated to reflux at 45 °C for 18 h, then cooled to
r.t. and worked up purified as before to give the title compound 24.
Yield: 0.033 g (84%); white solid; mp 52–53 °C; Rf 0.42 (7:2, pet-
rol/EtOAc); [α]D21 +2.5 (c 1.7, CHCl3).
MS: m/z [M + Na]+ calcd for C78H152O3Na: 1160.1634; found:
1160.1627.
1H NMR (500 MHz, CDCl3): δ = 3.74 (td, J = 4.8, 7.9 Hz, 1 H), 2.47 (td,
J = 5.4, 8.8 Hz, 1 H), 1.78–1.72 (m, 1 H), 1.67–1.60 (m, 2 H), 1.54–1.47
(m, 4 H), 1.45–1.07 (m, 129 H), 0.88 (t, J = 6.9 Hz, 6 H), 0.67–0.64 (m,
4 H), 0.57 (dt, J = 4.1, 8.2 Hz, 2 H), –0.33 (q, J = 4.9 Hz, 2 H).
13C NMR (126 MHz, CDCl3): δ = 179.5, 72.1, 50.7, 35.5, 31.9, 30.2, 29.8,
29.7, 29.65, 29.55, 29.5, 29.44, 29.4, 28.6, 27.4, 25.7, 22.6, 15.9, 14.0,
10.8.
IR: 3317, 2922, 2852, 1681, 1464, 1377, 721 cm–1.
5-((S)-3-((1R,2R)-2-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)cyclopro-
pyl)butylsulfonyl)-1-phenyl-1H-tetrazole (27)
(a) Diethyl azodicarboxylate (10.6 g, 60.8 mmol) in anhydrous THF
(15 mL) was added to a stirred solution of (S)-3-[(1R,2R)-2-((S)-2,2-
dimethyl[1,3]dioxolan-4-yl)cyclopropyl]butan-1-ol 2626 (10.0 g, 46.7
mmol), triphenylphosphine (17.2 g, 65.5 mmol) and 1-phenyl-1H-
tetrazole-5-thiol (11.6 g, 65.0 mmol) in anhydrous THF (100 mL) at
0 °C, allowed to reach r.t. and stirred overnight, then the solvent was
evaporated and the residue was heated at reflux with petroleum/EtO-
Ac (5:2, 150 mL) for 1 h and filtered. The filtrate was evaporated; col-
umn chromatography eluting with petroleum/EtOAc (5:2) gave 5-
((S)-3-((1R,2R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)cyclopro-
pyl)butylthio)-1-phenyl-1H-tetrazole.
Yield: 16 g (91%); pale-yellow oil; [α]D22 –34 (c 1.4, CHCl3).
MS: m/z [M + Na]+ calcd for C19H26N4NaO2S: 397.1674; found:
397.1630.
1H NMR (500 MHz, CDCl3): δ = 7.54–7.49 (m, 5 H), 4.0 (dd, J = 6.0,
7.9 Hz, 1 H), 3.72 (br q, J = 7.8 Hz, 1 H), 3.62 (br.t, J = 7.6 Hz, 1 H),
3.50–3.45 (m, 1 H), 3.31–3.25 (m, 1 H), 1.84–1.73 (m, 1 H), 1.71–1.67
(m, 1 H), 1.39 (s, 3 H), 1.28 (s, 3 H), 1.24–1.20 (m, 1 H), 1.04 (d, J =
6.6 Hz, 3 H), 0.96–0.91 (m, 1 H), 0.82 (dt, J = 5.6, 8.5 Hz, 1 H), 0.79–
0.69 (m, 1 H), 0.25 (br q, J = 5.6 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 171.2, 154.2, 133.6, 130.1, 129.7,
123.8, 108.4, 77.2, 70.0, 36.5, 32.9, 30.9, 26.8, 25.7, 23.4, 19.5, 19.2,
8.6.
IR: 2984, 2831, 1597, 1500, 1379, 1059, 853, 761 cm–1.
(b) A solution of ammonium molybdate(VI) tetrahydrate (24.7 g, 20.0
mmol) in 35% H2O2 (40 mL) was cooled in an ice bath and added to a
stirred solution of the above tetrazole (15.0 g, 40.0 mmol) in THF (140
mL) and IMS (300 mL) at 10 °C and stirred at r.t. for 2 h. A further solu-
tion of ammonium molybdate(VI) tetrahydrate (12.4 g, 10.0 mmol) in
35% H2O2 (20 mL) was added and the mixture was stirred at r.t. for 18
h. The mixture was poured into water (1.5 L) and extracted with
CH2Cl2 (1 × 300 mL, 3 × 50 mL). The combined organic layers were
washed with water (500 mL), and the solvent was evaporated. Col-
umn chromatography eluting with petroleum/EtOAc (5:2 then 1:1)
gave the title compound 27.
Yield: 14 g (87%); yellow oil; [α]D20 –37 (c 1.8, CHCl3).
MS: m/z found [M + Na]+: 429.1528; C19H26N4NaO4S requires:
429.1572.
1H NMR (500 MHz, CDCl3): δ = 7.67–7.65 (m, 2 H), 7.60–7.54 (m, 3 H),
4.08 (br dd, J = 5.4, 7.8 Hz, 1 H), 3.82–3.76 (m, 2 H), 3.70 (dd, J = 5.5,
10.1 Hz, 1 H), 3.64 (t, J = 7.8 Hz, 1 H), 2.03–1.96 (m, 1 H), 1.86–1.78
(m, 1 H), 1.39 (s, 3 H), 1.37–1.33 (m, 1 H), 1.30 (s, 3 H), 1.06 (d, J =
6.6 Hz, 3 H), 0.99–0.92 (m, 1 H), 0.82 (dt, J = 4.7, 8.8 Hz, 1 H), 0.72–
0.66 (m, 1 H), 0.31 (br q, J = 5.4 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 153.2, 132.8, 131.3, 129.5, 124.9,
108.4, 76.2, 69.8, 53.8, 32.0, 30.7, 28.7, 26.6, 25.5, 22.8, 19.5, 19.1, 8.1.
IR: 2985, 2834, 1595, 1498, 1339, 1152, 1059, 853, 764 cm–1.
(S)-2,2-Dimethyl-4-((1R,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclo-
propyl)hexadecane-2-yl)cyclopropyl)-1,3-dioxolane (28)
LiHMDS (14.6 mL, 15.0 mmol, 1.06 M) was added dropwise to a
stirred solution of aldehyde 25 (4.3 g, 9.0 mmol) and sulfone 27 (4.2 g,
10.3 mmol) in anhydrous THF (50 mL) under nitrogen at –10 °C. The
mixture was allowed to reach r.t. and stirred for 2 h, then worked up
as above to give (S)-2,2-dimethyl-4-((1R,2R)-2-[(E/Z)-((S)-16-Georg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 103–116
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1,3-dioxolane (4.6 g, 78%) as a colourless oil. Dipotassium azodicar-
boxylate (4.5 g, 23.2 mmol) was added to a stirred solution of the
above [1,3]-dioxolane (4.6 g, 7.0 mmol) in THF (40 mL) and MeOH (15
mL) under nitrogen at 10 °C. A solution of glacial acetic acid (6 mL)
and THF (6 mL) was added dropwise for 24 h then additional dipotas-
sium azodicarboxylate (2.3 g, 11.6 mmol) and a solution of glacial
acetic acid (3 mL) and THF (3 mL) were added and stirred for a further
24 h. The reaction was worked up as above to give the title compound
28.
Yield: 3.9 g (84%); thick oil; [α]D22 –8.5 (c 0.6, CHCl3).
MS: m/z [M + Na]+ calcd for C45H86O2Na: 681.6526; found: 681.6556.
1H NMR (500 MHz, CDCl3): δ = 4.13–4.06 (m, 1 H), 3.75–3.65 (m, 2 H),
1.45 (s, 3 H), 1.37–1.13 (br m, including 3 H s at δ 1.36, 67 H), 0.99 (br
s, 3 H), 0.88 (t, J = 6.3 Hz, 3 H), 0.83 (dt, J = 4.5, 8 Hz, 1 H), 0.71–0.65
(m, 3 H), 0.57 (dt, J = 4.1, 8.5 Hz, 1 H), 0.23 (br q, J = 5.4 Hz, 1 H), –0.33
(br q, J = 5.1 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 108.2, 77.9, 70.0, 37.4, 33.2, 31.9, 30.0,
29.6, 29.3, 28.7, 27.1, 26.8, 25.7, 23.8, 22.6, 20.0, 19.2, 15.7, 14.1, 10.9,
9.0.
IR: 2928, 2848, 1607, 1467, 1369, 1159, 1063, 824, 720 cm–1.
cis-(1R,2R)-2-((S)-16-((1S,2R)-2-Octadecylcyclopropyl)hexadec-
ane-2-yl)cyclopropanecarbaldehyde (29)
Periodic acid (3.3 g, 17.1 mmol) was added to stirred solution of the
acetal 28 (3.8 g, 5.8 mmol) in anhydrous ether (60 mL) under nitrogen
at r.t. The mixture was stirred for 16 h, then worked up as above to
give the aldehyde 29.
Yield: 3.1 g (94%); white solid; mp 37–38 °C; [α]D22 –0.015 (c 1.2, CH-
Cl3).
MS: m/z [M + Na]+ calcd for C41H78ONa: 609.5950; found: 609.5924.
1H NMR (500 MHz, CDCl3): δ = 9.33 (br d, J = 5.7 Hz, 1 H), 1.94–1.87
(m, 1 H), 1.37–1.14 (br m, 66 H), 1.05 (br d, J = 6.6 Hz, 3 H), 0.88 (t, J =
6.5 Hz, 3 H), 0.68–0.60 (m, 2 H), 0.56 (dt, J = 4.1, 8.2 Hz, 1 H), –0.33 (br
q, J = 5.1 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 201.7, 37.4, 32.5, 32.2, 31.9, 30.2, 29.8,
29.6, 29.5, 29.4, 29.3, 29.1, 28.8, 28.7, 28.5, 26.7, 22.6, 20.1, 15.7, 14.1,
13.6, 10.8.
IR: 2920, 2849, 1692, 1468, 1402, 825, 720 cm–1.
trans-(1S,2R)-2-((S)-16-((1S,2R)-2-Octadecylcyclopropyl)hexade-
can-2-yl)cyclopropanecarbaldehyde (30)
Sodium methoxide (0.60 g, 11 mmol) was added to a stirred solution
of cis-aldehyde 29 (3.5 g, 6.0 mmol) in MeOH (20 mL) and THF (30
mL) and heated at reflux for 56 h. The mixture was cooled to r.t. and
worked up as above to give the trans-aldehyde 30.
Yield: 2.7 g (77%); semi-solid; [α]D20 +8.5 (c 1.0, CHCl3).
MS: m/z [M + Na]+ calcd for C41H78ONa: 609.5950; found: 609.5938.
1H NMR (500 MHz, CDCl3): 8.99 (d, J = 5.7 Hz, 1 H), 1.71–1.66 (m, 1 H),
1.38–1.17 (br m, 65 H), 0.98 (d, J = 6.6 Hz, 3 H), 0.95–0.91 (m, 1 H),
0.88 (br t, J = 6.9 Hz, 3 H), 0.69–0.64 (m, 2 H), 0.56 (dt, J = 4.1, 8.2 Hz,
1 H), –0.33 (q, J = 5.4 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 201.0, 36.8, 31.9, 30.4, 30.2, 29.8, 29.6,
29.6, 29.3, 29.3, 28.7, 27.0, 22.6, 19.3, 15.7, 14.1, 13.2, 10.9.
IR: 2917, 2810, 1698, 1471, 1376, 1170, 1035, 925, 718 cm–1.
16-((1S,2R)-2-((S)-16-((1S,2R)-2-Octadecylcyclopropyl)hexadecan-
2-yl)cyclopropyl)hexadecanal (33)
(a) LiHMDS (6.8 mL, 7.2 mmol, 1.06 M) was added dropwise to a
stirred solution of trans-aldehyde 30 (2.7 g, 4.6 mmol) and 15-(1-
phenyl-1H-tetrazol-5-ylsulfonyl)pentadecyl pivalate 32 (2.5 g, 4.8
mmol) in anhydrous THF (30 mL) under nitrogen at –10 °C. The mix-
ture was allowed to reach r.t. and stirred for 2 h, then worked up as
above to give a thick oil, which solidified later as a mixture of (E/Z)-
16-((1S,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclopropyl)hexadec-ane-
2-yl)cyclopropyl)hexadec-15-enyl pivalates (3.8 g, 94%). Dipotassium
azodicarboxylate (4.5 g, 23 mmol) was added to a stirred solution of
the above alkene (3.8 g, 4.3 mmol) in THF (30 mL) and MeOH (15 mL)
under nitrogen at 10 °C. A solution of glacial acetic acid (6 mL) and
THF (6 mL) was added dropwise for 24 h then additional dipotassium
azodicarboxylate (2.3 g, 11.6 mmol) and a solution of glacial acetic
acid (3 mL) and THF (3 mL) were added and stirred for a further 24 h.
The reaction was worked up as above to give 16-((1S,2R)-2-((S)-16-
((1S,2R)-2-octadecylcyclopropyl)hexadecane-2-yl)cyclopropyl)hexa-
decyl pivalate.
Yield: 2.78 g (73%); colourless oil; [α]D22 +4.04 (c 1.46, CHCl3).
MS: m/z [M + Na]+ calcd for C61H118O2Na: 905.9030; found: 905.9051.
1H NMR (500 MHz, CDCl3): δ = 4.05 (br t, J = 6.6 Hz, 2 H), 1.67–1.58
(m, 4 H), 1.38–1.26 (br m, 88 H), 1.20 (s, 9 H), 0.90 (d, J = 6.6 Hz, 3 H),
0.88 (t, J = 7.2 Hz, 3 H), 0.69–0.64 (m, 3 H), 0.56 (dt, J = 3.9, 7.8 Hz,
1 H), 0.48–0.42 (m, 1 H), 0.21–0.09 (m, 3 H), –0.32 (br q, J = 5.4 Hz,
1 H).
13C NMR (126 MHz, CDCl3): δ = 178.6, 64.4, 38.7, 38.1, 37.4, 34.4, 31.9,
30.2, 30.0, 29.7, 29.6, 29.6, 29.5, 29.3, 29.2, 28.7, 28.6, 27.2, 27.2, 26.1,
25.9, 26.1, 25.9, 22.6, 22.3, 19.6, 18.6, 15.8, 14.0, 10.9, 10.4.
IR: 2920, 2810, 1732, 1470, 1153 cm–1.
(b) The above pivalate (2.78 g, 3.13 mmol) was added to a stirred solu-
tion of potassium hydroxide (0.7 g, 12.5 mmol) dissolved in a mixture
of THF/MeOH/water (30:20:5 mL). The mixture was stirred at 70 °C
for 3 h, then worked up as above to give 16-((1S,2R)-2-((S)-16-
((1S,2R)-2-octadecylcyclopropyl)hexadecane-2-yl)cyclopropyl)hexa-
decan-1-ol.
Yield: 1.5 g (60%); white solid; mp 50–52 °C; [α]D22 +3.8 (c 1.1, CHCl3).
MS: m/z [M + Na]+ calcd for C56H110ONa: 821.8454; found: 821.8462.
1H NMR (500 MHz, CDCl3): δ = 3.65 (br t, J = 6.6 Hz, 2 H), 1.62–1.54
(m, including br s for hydroxyl group, 10 H), 1.37–1.17 (br m, 83 H),
0.9 (d, J = 6.6 Hz, 3 H), 0.89 (t, J = 6.6 Hz, 3 H), 0.68–0.62 (m, 3 H), 0.57
(dt, J = 3.8, 7.9 Hz, 1 H), 0.47–0.42 (m, 1 H), 0.22–0.09 (m, 3 H), –0.32
(br q, J = 5.4 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 63.1, 38.1, 37.4, 34.4, 32.8, 31.9, 30.2,
30.0, 29.7, 29.6, 29.4, 29.3, 28.7, 27.2, 26.1, 25.7, 22.6, 19.6, 18.6, 15.8,
14.0, 10.9, 10.4.
IR: 3419, 2918, 2845, 1471, 1366, 1057, 898, 719 cm–1.
(c) The above alcohol (1.50 g, 1.9 mmol) was dissolved in hot CH2Cl2
(20 mL) and added to a refluxing stirred suspension of PCC (0.94 g, 4.4
mmol) in CH2Cl2 (40 mL). The mixture was stirred vigorously for 2 h,
then worked up as above to give aldehyde 33.
Yield: 1.24 g (85%); white solid; mp 40–42 °C; [α]D24 +5.9 (c 1.0,
CHCl3).
MS: m/z [M + Na]+ calcd for C56H108ONa: 819.8298; found: 819.8280.Georg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 103–116
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7.2 Hz, 2 H), 1.63 (br pent, J = 7.2 Hz, 2 H), 1.42–1.23 (br m, 78 H),
1.21–1.09 (m, 10 H), 0.90 (d, J = 6.6 Hz, 3 H), 0.89 (t, J = 6.6 Hz, 3 H),
0.69–0.64 (m, 3 H), 0.57 (dt, J = 4.1, 8.2 Hz, 1 H), 0.47–0.42 (m, 1 H),
0.22–0.09 (m, 3 H), –0.32 (br q, J = 5.1 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 202.8, 43.9, 38.1, 37.4, 34.4, 31.9, 30.2,
30.0, 29.7, 29.6, 29.6, 29.4, 29.3, 29.1, 29.0, 28.7, 27.6, 27.2, 26.1, 22.6,
22.1, 20.4, 19.6, 19.4, 18.6, 15.7, 14.2, 14.0, 11.4, 10.9, 10.4.
IR: 2920, 2810, 1707, 1470, 1019, 845, 718 cm–1.
Methyl (R)-2-((R)-1-(tert-Butyldimethylsilyloxy)-19-((1S,2R)-2-
((S)-16-((1S,2R)-2-octadecylcyclopropyl)hexadecane-2-yl)cyclo-
propyl)nonadecyl)tetracosanoate (36)
LiHMDS (2.4 mL, 2.5 mmol, 1.06 M) was added dropwise to a stirred
solution of aldehyde 33 (1.2 g, 1.5 mmol) and methyl (R)-2-((R)-1-
(tert-butyldimethylsilyloxy)-3-(1-phenyl-1H-tetrazol-5-ylthio)pro-
pyl)tetracosanoate 3535 (1.27 g, 1.60 mmol) in anhydrous THF (30 mL)
under nitrogen at –10 °C. The reaction was allowed to reach r.t. and
stirred for 2 h, then worked up as above to give a colourless oil as a
mixture of (E/Z) methyl (R)-2-((R)-1-(tert-butyldimethylsilyloxy)-19-
((1S,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclopropyl)hexadecane-2-
yl)cyclopropyl)nonadec-4-enyl)tetracosanoates (1.7 g, 85%). Dipotas-
sium azodicarboxylate (2.0 g, 10.3 mmol) was added to a stirred solu-
tion of the above alkenes (2.5 g, 1.9 mmol) in THF (25 mL) and MeOH
(15 mL) at 5 °C. A solution of glacial acetic acid (3 mL) and THF (3 mL)
was added dropwise for 24 h then additional dipotassium azodicar-
boxylate (1.5 g, 7.7 mmol) and a solution of glacial acetic acid (2 mL)
and THF (2 mL) were added and stirred for a further 24 h. The mixture
was worked up as above to give methyl (R)-2-((R)-1-(tert-butyldi-
methylsilyloxy)-19-((1S,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclopro-
pyl)hexadecane-2-yl)cyclopropyl)nonadecyl)tetracosanoate 36.
Yield: 1.41 g (83%); colourless oil; [α]D25 +4.3 (c 0.81, CHCl3).
MS: m/z [M + Na]+ calcd for C90H178O3SiNa: 1358.3443; found:
1358.3410.
1H NMR (500 MHz, CDCl3): δ = 3.92–3.89 (m, 1 H), 3.66 (s, 3 H), 2.53
(ddd, J = 3.7, 7.2, 11.0 Hz, 1 H), 1.57 (br s, 8 H), 1.37–1.10 (br m,
132 H), 0.91–0.84 (m, including d integrating to 3 H, t integrating to
6 H and s integrating to 9 H, 18 H), 0.70–0.65 (m, 3 H), 0.56 (dt, J = 3.7,
8.1 Hz, 1 H), 0.48–0.42 (m, 1 H), 0.21–0.078 (m, 3 H), 0.049 (s, 3 H),
0.025 (s, 3 H), –0.32 (br q, J = 5.1 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 175.1, 73.2, 51.5, 51.1, 38.1, 37.4, 33.7,
31.9, 30.2, 30.0, 29.8, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 28.7, 27.5, 27.2,
26.1, 25.7, 23.7, 22.6, 19.6, 18.6, 17.9, 15.7, 14.1, 10.9, 10.4, –4.3, –4.9.
IR: 2923, 2813, 1741, 1465, 1361, 1254, 1166, 836, 775 cm–1.
(R)-2-((R)-1-Hydroxy-19-((1S,2R)-2-((S)-16-((1S,2R)-2-octadecyl-
cyclopropyl)hexadecane-2-yl)cyclopropyl)nonadecyl)tetracosa-
noic Acid (37)
(a) Ester 36 (1.41 g, 1.05 mmol) was dissolved in anhydrous THF (15
mL) in a anhydrous polyethylene vial and stirred under nitrogen at r.t.
Pyridine (0.3 mL) and hydrogen fluoride-pyridine complex (1.1 mL,
0.77 mmol) were added and the mixture was stirred for 17 h at 45 °C,
then worked up as above to give methyl (R)-2-((R)-1-hydroxy-19-
((1S,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclopropyl)hexadecane-2-
yl)cyclopropyl)nonadecyl)tetracosanoate.
Yield: 0.92 g (72%); white solid; mp 48–49 °C; [α]D23 +8.6 (c 0.18,
CHCl3).
MS: m/z [M + Na]+ calcd for C84H164O3Na: 1244.2578; found:
1244.2605.
1H NMR (500 MHz, CDCl3): δ = 3.71 (s, 3 H), 3.70–3.66 (m, 1 H), 2.46–
2.40 (m, 1 H), 1.74–1.69 (m, 1 H, for OH), 1.26–1.13 (br m, 140 H),
0.90–0.81 (m, including d integrating to 3 H and t integrating to 6 H,
9 H), 0.70–0.65 (m, 3 H), 0.57 (dt, J = 4.1, 7.9 Hz, 1 H), 0.48–0.42 (m,
1 H), 0.22–0.09 (m, 3 H), –0.31 ( br q, J = 5.1 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 176.2, 72.3, 51.4, 50.9, 38.1, 37.4, 35.7,
34.4, 31.9, 30.3, 30.2, 30.0, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 28.8, 28.7,
27.4, 27.2, 26.1, 25.7, 22.6, 22.6, 22.3, 19.6, 18.6, 15.7, 14.1, 10.9, 10.4.
IR: 3420, 2917, 2810, 1715, 1618, 1468, 1375, 1196, 720 cm–1.
(b) Lithium hydroxide monohydrate (0.47 g, 11.2 mmol) was added to
a stirred solution of the above ester (0.92 g, 7.5 mmol) in THF (12 mL),
MeOH (1.5 mL) and water (2 mL) at r.t. The mixture was stirred at
45 °C for 18 h, then cooled to r.t. and worked up as above to give the
title acid 37.
Yield: 0.63 g (70%); white solid; mp 55–56 °C; Rf 0.42 (7:2
petrol/EtOAc); [α]D22 +5.2 (c 0.50, CHCl3).
MALDI MS: m/z [M + Na]+ calcd for C83H162O3Na: 1230.25; found:
1230.24.
1H NMR (500 MHz, CDCl3): δ = 3.74–3.71 (m, 1 H), 2.47 (td, J = 5.0,
10.4 Hz, 1 H), 1.69–1.58 (m, 2 H), 1.55–1.47 (m, 2 H), 1.41–1.34 (m,
4 H), 1.24–1.01 (br m, 134 H), 0.9 (d, J = 6.6 Hz, 3 H, α-Me), 0.88 (t, J =
6.6 Hz, 6 H, terminal 2 × CH3), 0.70–0.64 (m, 3 H, 2 × CH-cis-cyclopro-
pane and CHCH3), 0.57 (dt, J = 3.7, 7.8 Hz, 1 H), 0.48–0.42 (m, 1 H),
0.22–0.09 (m, 3 H), –0.32 (br q, J = 5.1 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 179.5, 72.1, 50.7, 38.1, 37.4, 35.5, 34.5,
31.9, 30.2, 30.0, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 28.7, 27.3, 27.2, 26.1,
25.7, 22.6, 19.6, 18.6, 15.7, 14.1, 10.9, 10.4.
IR: 3411, 2919, 2810, 1689, 1470, 1191, 1016, 720 cm–1.
(R)-2-((R)-1-Hydroxy-19-((1S,2R)-2-((S)-16-((1R,2S)-2-Octadecyl-
cyclopropyl)hexadecane-2-yl)cyclopropyl)nonadecyl)tetracosa-
noic Acid (38)
(a) Methyl (R)-2-((R)-1-(tert-Butyldimethylsilyloxy)-19-((1S,2R)-2-
((S)-16-((1R,2S)-2-octadecylcyclopropyl)hexadecane-2-yl)cyclopro-
pyl)nonadecyl)tetracosanoate (see the Supporting Information) (0.95
g, 0.71 mmol) was dissolved in anhydrous THF (12 mL) in a dry poly-
ethylene vial and stirred under nitrogen at r.t. Pyridine (0.2 mL) and
hydrogen fluoride-pyridine complex (0.7 mL, 0.47 mmol) were added
and the mixture was stirred for 17 h at 45 °C, then diluted with petro-
leum/EtOAc (10:1, 70 mL) and neutralised with sat. aq. NaHCO3 until
no more carbon dioxide was liberated. The aqueous layer was re-ex-
tracted with petroleum/EtOAc (10:1, 2 ×50 mL). The combined organ-
ic layers were washed with brine, dried and evaporated; column chro-
matography eluting with petroleum/EtOAc (20:1) gave methyl (R)-2-
((R)-1-hydroxy-19-((1S,2R)-2-((S)-16-((1R,2S)-2-octadecylcyclopro-
pyl)hexadecane-2-yl)cyclopropyl)nonadecyl)tetracosanoate.
Yield: 0.73 g (72%); white solid; mp 47–48 °C; [α]D22 +8.1 (c 0.19,
CHCl3) .
MS: m/z [M + Na]+ calcd for C84H164O3Na: 1244.2578; found:
1244.2612.
1H NMR (500 MHz, CDCl3): δ = 3.71 (s, 3 H), 3.68–3.63 (m, 1 H), 2.49–
2.36 (m, 1 H), 2.05 (br s, 1 H, for hydroxyl group), 1.37–1.14 (br m,
140 H), 0.90–0.81 (m, including d integrating to 3 H and t integrating
to 6 H, 9 H), 0.68–0.63 (m, 3 H), 0.57 (dt, J = 4.1, 7.8 Hz, 1 H), 0.48–
0.42 (m, 1 H), 0.21–0.10 (m, 3 H), –0.31 (br q, J = 5.3 Hz, 1 H).
13C NMR (126 MHz, CDCl3): δ = 176.2, 72.3, 51.4, 50.9, 38.1, 37.4, 36.3,
35.7, 34.5, 34.1, 33.7, 31.9, 31.5, 30.3, 30.2, 30.0, 29.7, 29.5, 29.4, 29.3,
29.0, 28.8, 28.7, 27.6, 27.4, 27.2, 26.1, 25.8, 25.7, 22.6, 22.3, 22.1, 20.4,
19.6, 19.4, 18.6, 15.7, 14.2, 14.1, 14.0, 11.7, 10.9, 10.4, 8.8.Georg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 103–116
115
C. Don Lawson et al. PaperSyn OpenIR: 3419, 2917, 2810, 1712, 1618, 1470, 1375, 1197, 719 cm–1.
(b) Lithium hydroxide monohydrate (0.38 g, 9.1 mmol) was added to
a stirred solution of the above methyl ester (0.73 g, 0.61 mmol) in THF
(12 mL), MeOH (1.5 mL) and water (2 mL) at r.t. The mixture was
stirred at 45–50 °C for 18 h, then cooled to r.t. and quenched with sat.
aq. NH4Cl (15 mL) then acidified to pH 1 with 5 % HCl and the product
was extracted with petroleum/EtOAc (5:1, 3 × 30 mL). The combined
organic layers were washed with water (20 mL), dried and evaporat-
ed. Column chromatography eluting with petroleum/EtOAc (7:2) gave
the title acid 38.
Yield: 0.61 g (84%); white solid; mp 54–55 °C; Rf 0.42 (above solvent);
[α]D24 +5.5 (c 0.60, CHCl3).
MALDI MS: m/z found [M + Na]+: 1230.2; C83H162O3Na requires:
1230.2.
1H NMR (500 MHz, CDCl3): δ = 3.74–3.71 (m, 1 H), 2.47 (td, J = 5.0,
9.7 Hz, 1 H), 1.76–1.49 (m, 21 H), 1.58–1.14 (br m, 121 H), 0.9 (d, J =
6.9 Hz, 3 H, α-Me), 0.88 (t, J = 6.6 Hz, 6 H, terminal 2 × CH3), 0.69–0.61
(m, 3 H, 2 × CH-cis-cyclopropane and CHCH3), 0.57 (dt, J = 4.1, 8.2 Hz,
1 H), 0.46–0.42 (m, 1 H), 0.22–0.09 (m, 3 H), –0.32 (br q, J = 5.4 Hz,
1 H).
13C NMR (126 MHz, CDCl3): δ = 179.5, 72.1, 50.8, 38.1, 37.4, 35.5, 34.5,
31.9, 30.2, 30.0, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 28.7, 27.3, 27.2, 26.1,
25.7, 22.6, 19.6, 18.6, 15.7, 14.1, 10.9, 10.4.
IR: 3418, 2918, 2819, 1685, 1470, 1205, 1020, 719 cm–1.
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